Milestone Pharmaceuticals’ etripamil nasal spray has received China approval for adults with PSVT, triggering a $2.0 million milestone payment. The decision opens an exclusive Greater China commercialization arrangement with Everest Medicines, while Milestone remains eligible for up to $98.0 million in additional milestones and tiered royalties reaching 18% on future sales.
Key Highlights
- Tiered royalties on future Greater China etripamil sales may reach 18%.
- Etripamil nasal spray won approval in China for adults with PSVT.
- The approval triggered a $2.0 million milestone payment.
- Everest Medicines holds the exclusive Greater China commercialization license, covering Mainland China, Hong Kong, Macau and Taiwan.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) said etripamil nasal spray won approval in China for adults with PSVT, triggering a $2.0 million milestone payment. The decision is the first approval for etripamil outside the United States and gives Everest Medicines the exclusive Greater China commercialization license.
China Approval Opens Everest Commercialization
Everest Medicines will lead commercialization across Greater China, defined in the announcement as Mainland China, Hong Kong, Macau and Taiwan. The approval relied on results from the global key RAPID study and the China-based JX02002 study.
FAQs
Q: What did China approve for Milestone Pharmaceuticals?
A: China’s National Medical Products Administration approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia in adults, marking the product’s first approval outside the United States.
Q: What payment does the China approval trigger for MIST?
A: The China approval triggers a $2.0 million milestone payment to Milestone Pharmaceuticals. The Greater China license also includes potential future milestones and royalties.
Q: What approval did etripamil receive in China?
A: Etripamil nasal spray won approval in China for adults with PSVT. It is the product’s first approval outside the United States.
Q: What role will Everest Medicines have after the approval?
A: Everest Medicines received the exclusive Greater China commercialization license. The territory includes Mainland China, Hong Kong, Macau and Taiwan, and Everest will lead commercialization there.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.